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Abstract 
Review on t(5;9)(q14.1;p24) SSBP2/JAK2, with 
data on clinics, and the genes implicated. 
Identity 
Other names 
SSBP2-JAK2 fusion 
Clinics and pathology 
Disease 
B-lymphoblastic leukemia/lymphoma 
Phenotype/cell stem origin 
CD45+(dim), TdT+, CD34+(subset), HLA-DR+, 
CD19+, CD10+, and CD20+(variable) with weak 
aberrant expression of the myeloid markers CD13 
and CD33; no expression of surface 
immunoglobulin, T lymphoid, and other myeloid 
and monocytic markers. 
Epidemiology 
One reported case; 39-year-old male presenting 
with a white blood cell count of 400x109/L with 
98% blasts (Poitras et al., 2008). 
Treatment 
Prednisone, vincristine, doxorubicin, asparaginase, 
and high-dose methotrexate; achieved complete 
remission after 30 days of cytoreductive 
chemotherapy; also received prophylactic 
intrathecal chemotherapy and cranial radiation. 
Prognosis 
Rapid systemic relapse; 8 months after initial 
diagnosis the patient died from progressive disease. 
 
Cytogenetics 
Note 
t(5;9) detected in 19 of 20 GTG-banded metaphase 
cells analyzed from a 24-hr unstimulated bone 
marrow culture. 
Cytogenetics molecular 
The breakpoint on chromosome 9p was found to be 
distal to band p23 by FISH mapping on abnormal 
metaphase. The breakpoint was found to reside 
within the JAK2 locus by hybridizing a BAC 
spanning the JAK2 gene (RP11-927h16; 
nucleotides 4965192-5138016), which produced 
signals on both der(9) and der(5) chromosomes. 
Additional FISH mapping localized the 
chromosome 5 breakpoint to a 57.5 kb interval at 
5q14.1 spanning SSBP2, with RP11-120L4 
(nucleotides 80698679-80848640) and RP11-
147O19 (nucleotides 80861153-81023195) flanking 
the breakpoint; the presence of the SSBP2-JAK2 
transcript was confirmed by RT-PCR. 
Additional anomalies 
With disease progression, a subsequent sample 
revealed additional chromosome aberrations: 
46,XY,t(5;9)(q14.1;p24.1) [cp10]/46,idem, 
t(1;13)(p22;q32), 
t(15;20)(q15;q13)[3]/46,idem,t(1;3)(p36;p21),del(1
2)(q12q13)[cp7]. 
Genes involved and 
proteins 
SSBP2 
Location 
5q14.1 
t(5;9)(q14.1;p24) SSBP2/JAK2 Morgan EA, Dal Cin P 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2014; 19(1) 60 
 
a). Partial GTG-banded karyotypes showing the t(5;9)(q14.1;p24.1). b). Partial FISH analysis showing the 5'JAK2 hybridization 
signal on der(5), the 3'JAK2 hybridization signal on der(9) and an intact JAK2 hybridization signal on the normal chromosome 9. 
 
 
DNA/RNA 
17 exons. 
Protein 
Single-stranded DNA-binding complex; plays role 
in the maintenance of genome stability. 
JAK2 
Location 
9p24 
DNA/RNA 
24 exons. 
Protein 
Tyrosine kinase; cytokine receptor signaling. 
Result of the chromosomal 
anomaly 
Hybrid gene 
Description 
5'SSBP2-3'JAK2. 
Transcript 
RT-PCR using the forward primer in exon 3 of 
SSBP2 and the reverse primer in exon 12 of JAK2 
yielded three discrete products of 465 bp, 375 bp,  
 
 
and 290 bp; sequencing revealed that each 
contained the same 3' JAK2 sequences (exon 11 
and downstream 3' sequence), but different joining 
5' SSBP2 sequences (junction occurred at the 3' end 
of SSBP2 exons 5, 4, and 3, respectively termed 
T1-T3). 
Fusion protein 
Description 
It is predicted that T1 and T2, which are both in-
frame, will encode SSBP2-JAK2 fusion proteins 
containing the SSBP2 Lissencephaly type I-like 
homology (LisH) motif as well as the JH2 and JH1 
domains of JAK2; the T3 fusion is out of frame and 
may encode a truncated SSBP2 protein with a 
COOH-terminal deletion of the proline-rich, 
glycine-rich, and downstream regions. 
Oncogenesis 
Other JAK2 fusions with other partners genes 
PCM1 (8p22), BCR (22q11.2) and ETV6 (12p13) 
lead to dimerization of adjacent, receptor-associated 
JAKs, and ensuing auto- and trans-phosphorylation 
causing constitutive kinase activation (Lacronique 
et al., 1997); it is predicted that the LisH 
(Lissencephaly type I-like homology) motif in 
SSBP2 may permit a similar mechanism of JAK2 
activation. 
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To be noted 
Note 
JAK2 fusion proteins have been described in 
several hematopoietic neoplasms including acute 
leukemias and myeloproliferative neoplasms. The 
fusion partners reported in B-lineage acute 
lymphoblastic leukemia (ALL) include ETV6 
(Peeters et al., 1997), PCM1 (Reiter et al., 2005), 
PAX5 (Nebral et al., 2009), BCR and STRN3 
(Roberts et al., 2012). It is thought that these 
fusions result in constitutive JAK2 tyrosine kinase 
activity, and it is predicted that patients with B-
ALL exhibiting one of these fusions may respond to 
JAK2 inhibitors (Lacronique et al., 1997; Roberts et 
al., 2012). This is clinically relevant given that at 
least the PAX5-JAK2, BCR-JAK2 and STRN3-
JAK2 fusions have been associated with a group of 
high-risk B-lineage ALLs known as BCR-ABL1 
negative ALL or "Ph-like ALL", which are 
characterized by a gene expression profile similar to 
BCR-ABL1-positive ALL, an alteration of IKZF1, 
and poor prognosis (Roberts et al., 2012). The 
translocation described herein describes an 
additional JAK2 fusion protein in B-lineage ALL 
(SSBP2-JAK2) (Poitras et al., 2008). 
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